Steven Cohen’s Protalix BioTherapeutics PLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$36K Sell
13,027
-12,539
-49% -$31.2K ﹤0.01% 3771
2026
Q2
$59.6K Buy
+25,566
New +$54.1K ﹤0.01% 3770

Other funds holding PLX

Steven Cohen's PLX Position: Q3 2026 in Review

Steven Cohen reduced its Protalix BioTherapeutics (PLX) stake by 49% in Q3 2026, selling an estimated $31.2K and leaving 13,027 shares worth $36K. The position accounts for ﹤0.01% of the portfolio, ranked #3771.

Steven Cohen first reported a position in PLX in Q2 2026 and has held it in 2 quarters since. The position peaked at $59.6K in Q2 2026. 107 funds tracked by Wall St. Rank hold PLX as of Q3 2026.

  • Steven Cohen held 13,027 shares of Protalix BioTherapeutics worth $36K as of Q3 2026.
  • Steven Cohen sold 12,539 Protalix BioTherapeutics shares in Q3 2026, an estimated $31.2K.
  • Protalix BioTherapeutics made up ﹤0.01% of Steven Cohen's portfolio in Q3 2026, its #3771 holding.
  • Steven Cohen first reported a position in Protalix BioTherapeutics in Q2 2026 and has held it in 2 quarters since.
  • Steven Cohen's Protalix BioTherapeutics position peaked at $59.6K in Q2 2026.
  • 107 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2026.

Based on Point72 Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.